BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17639394)

  • 1. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
    Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
    Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
    Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC
    Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
    Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
    Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
    Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
    Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
    Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck.
    Uygun K; Bilici A; Karagol H; Caloglu M; Cicin I; Aksu G; Fayda M; Uzunoglu S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):601-5. PubMed ID: 19123002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational research offers individually tailored treatments for cancer patients.
    Bartelink H; Begg AC; Martin JC; van Dijk M; Moonen L; van 't Veer LJ; Van de Vaart P; Verheij M
    Cancer J Sci Am; 2000; 6(1):2-10. PubMed ID: 10696731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
    Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
    IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
    Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
    Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
    Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
    Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
    Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
    Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.
    Yang Z; Schumaker LM; Egorin MJ; Zuhowski EG; Guo Z; Cullen KJ
    Clin Cancer Res; 2006 Oct; 12(19):5817-25. PubMed ID: 17020989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
    Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
    Fisch MJ; Howard KL; Einhorn LH; Sledge GW
    Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.